Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily ...

Shares in Danish drugmaker Novo Nordisk, maker of the blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, ...

Some experts say oral versions of popular weight-loss drugs such as Wegovy could offer people more flexibility and ...

Novo Nordisk's (NVO) stock price dropped following Eli Lilly's announcement of positive Phase 3 trial results for its oral ...

Guggenheim’s Seamus Fernandez cut his rating on Novo Nordisk stock to Hold from Buy on Thursday, as did Evan David Seigerman ...

The mid-stage trial results announced by the pharmaceutical giant showed that patients taking orforglipron lost an average of ...

A new review of clinical trial data finds evidence that GLP-1 drugs can meaningfully reduce dementia risk in people with type ...

Novo Nordisk's stocks face YTD struggles due to trial results and tariffs, but strong fundamentals and outlook justify a Buy.

Russian public procurements of drugs based on the active ingredient semaglutide, which is an original drug from Denmark’s ...

U.S.-listed shares of Novo Nordisk plunged 7% in intraday trading Thursday after rival Eli Lilly reported positive oral ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Novo Nordisk (NYSE: NVO) has seen revenue soar in recent years thanks to two drugs that have helped people around the world ...